Inspire Medical (NYSE:INSP) a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (OSA), reported financial results for the three-months ended March 31, 2018. As quoted in the press release: “We are extremely pleased with the significant momentum in our business,” said Tim …

As quoted in the press release:

“We are extremely pleased with the significant momentum in our business,” said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. “Our Inspire therapy for the treatment of moderate to severe OSA is gaining substantial traction with patients and physicians, as evidenced by our continued strong growth in revenues in the first quarter of 2018. We have now published data from approximately 775 patients, including a 300-patient registry study, highlighting their clinical experience with Inspire therapy, further supporting the efficacy and safety of our device for physicians, patients and payors. We look forward to the continued launch of our fourth-generation neurostimulator, Inspire IV, in Europe, during the second quarter.”
“We were also excited to successfully complete our IPO, which will enable us to hire additional sales and marketing personnel and expand marketing programs, both in the U.S. and in Europe, in order to target additional physicians and patients. In addition, we will continue to invest in product development and R&D to further enhance our technology platform,” continued Mr. Herbert. “We view this financing and the participation of many top-tier healthcare focused investors as validation of the significant growth potential of our business. We are grateful for the support of all of the investors who participated in the offering and are focused on creating long-term shareholder value.”

Click here to read the full press release.